Cargando…
Proposal of the Definition for COVID-19-Associated Coagulopathy
Thrombotic events are common complications in COVID-19 patients that include both thrombus formation in large vessels and the microvasculature of the lung and other organs. COVID-19-associated coagulopathy (CAC) and disseminated intravascular coagulation (DIC) have similarities and differences, and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827226/ https://www.ncbi.nlm.nih.gov/pubmed/33430431 http://dx.doi.org/10.3390/jcm10020191 |
_version_ | 1783640710939934720 |
---|---|
author | Iba, Toshiaki Warkentin, Theodore E. Thachil, Jecko Levi, Marcel Levy, Jerrold H. |
author_facet | Iba, Toshiaki Warkentin, Theodore E. Thachil, Jecko Levi, Marcel Levy, Jerrold H. |
author_sort | Iba, Toshiaki |
collection | PubMed |
description | Thrombotic events are common complications in COVID-19 patients that include both thrombus formation in large vessels and the microvasculature of the lung and other organs. COVID-19-associated coagulopathy (CAC) and disseminated intravascular coagulation (DIC) have similarities and differences, and whether CAC is a form of DIC is the subject of debate. Reported mechanisms of CAC include activated coagulation, endotheliopathy, up-regulated innate and adaptive immunity, and activated complement system. Although the clinical features and laboratory findings of CAC and DIC seem different, there are fundamental similarities that should be considered. Basically, the pathological findings of COVID-19 fall within the scope of the definition of DIC, i.e., systemic activation of coagulation caused by or resulting from the microvascular damage. Therefore, we suggest that although CAC differs from usual infection-associated DIC, its various features indicate that it can be considered a thrombotic phenotype DIC. This review summarizes the current knowledge about CAC including differences and similarities with sepsis-associated DIC. |
format | Online Article Text |
id | pubmed-7827226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78272262021-01-25 Proposal of the Definition for COVID-19-Associated Coagulopathy Iba, Toshiaki Warkentin, Theodore E. Thachil, Jecko Levi, Marcel Levy, Jerrold H. J Clin Med Review Thrombotic events are common complications in COVID-19 patients that include both thrombus formation in large vessels and the microvasculature of the lung and other organs. COVID-19-associated coagulopathy (CAC) and disseminated intravascular coagulation (DIC) have similarities and differences, and whether CAC is a form of DIC is the subject of debate. Reported mechanisms of CAC include activated coagulation, endotheliopathy, up-regulated innate and adaptive immunity, and activated complement system. Although the clinical features and laboratory findings of CAC and DIC seem different, there are fundamental similarities that should be considered. Basically, the pathological findings of COVID-19 fall within the scope of the definition of DIC, i.e., systemic activation of coagulation caused by or resulting from the microvascular damage. Therefore, we suggest that although CAC differs from usual infection-associated DIC, its various features indicate that it can be considered a thrombotic phenotype DIC. This review summarizes the current knowledge about CAC including differences and similarities with sepsis-associated DIC. MDPI 2021-01-07 /pmc/articles/PMC7827226/ /pubmed/33430431 http://dx.doi.org/10.3390/jcm10020191 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Iba, Toshiaki Warkentin, Theodore E. Thachil, Jecko Levi, Marcel Levy, Jerrold H. Proposal of the Definition for COVID-19-Associated Coagulopathy |
title | Proposal of the Definition for COVID-19-Associated Coagulopathy |
title_full | Proposal of the Definition for COVID-19-Associated Coagulopathy |
title_fullStr | Proposal of the Definition for COVID-19-Associated Coagulopathy |
title_full_unstemmed | Proposal of the Definition for COVID-19-Associated Coagulopathy |
title_short | Proposal of the Definition for COVID-19-Associated Coagulopathy |
title_sort | proposal of the definition for covid-19-associated coagulopathy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827226/ https://www.ncbi.nlm.nih.gov/pubmed/33430431 http://dx.doi.org/10.3390/jcm10020191 |
work_keys_str_mv | AT ibatoshiaki proposalofthedefinitionforcovid19associatedcoagulopathy AT warkentintheodoree proposalofthedefinitionforcovid19associatedcoagulopathy AT thachiljecko proposalofthedefinitionforcovid19associatedcoagulopathy AT levimarcel proposalofthedefinitionforcovid19associatedcoagulopathy AT levyjerroldh proposalofthedefinitionforcovid19associatedcoagulopathy |